Cryoniss

Executive Summary

Cryoniss is a UK-based preclinical biotechnology company specializing in regenerative medicine, with a focus on developing advanced cell therapies for degenerative diseases and serious injuries. Founded in 2017, the company leverages biologics and cellular engineering to harness the body's natural repair mechanisms. Its pipeline targets conditions in orthopedics and neurology, aiming to restore function through novel biologic interventions. As a private, early-stage entity with a small team (1-50 employees), Cryoniss has yet to disclose funding details or clinical data, but its innovative approach positions it in a high-growth sector. The company's potential hinges on successful preclinical validation and advancement toward clinical trials, which could attract partnerships or investment. However, with no disclosed pipelines or regulatory milestones, the risk remains high at this stage.

Upcoming Catalysts (preview)

• TBDPreclinical Proof-of-Concept Data Release30% success
• TBDSeries A Funding Round Announcement40% success
• TBDFirst IND Filing for Lead Program20% success